China Launches Drug Price Comparison Tool for Lower Costs

China has achieved full national coverage of its medical insurance drug price comparison mini-program, with all 31 provinces, autonomous regions, municipalities, and the Xinjiang Production and Construction Corps now offering the service, according to People’s Daily. Dubbed the “price comparison magic tool” (比价神器), the digital platform allows patients to compare drug prices across pharmacies and hospitals, promoting transparency and reducing out-of-pocket costs for essential medications.

The initiative, led by the National Healthcare Security Administration (NHSA), addresses a long-standing pain point for Chinese consumers: opaque drug pricing outside of hospitals. For years, retail pharmacy prices varied widely for identical medications, with no unified reference system available to consumers.

How the Tool Works

Patients access the mini-program through the “National Medical Insurance Service Platform” app, entering the local section and opening the drug price comparison module. By searching a drug name, users can view average local prices, nearby pharmacy prices, distances, and stock availability, with intelligent sorting for easy comparison.

“Insured individuals simply need to enter the local section of the National Medical Insurance Service Platform app, open the ‘Medical Insurance Drug Price Comparison’ module, enter the drug name, and they can view the average local drug price as well as nearby pharmacy prices, distances, and stock information,” Chen Qiywei, Director of the Beijing Medical Insurance Bureau’s Price and Procurement Division, explained in the People’s Daily report.

The mini-program is accessible via WeChat, Alipay, or dedicated medical insurance apps. Some provinces have added photo-recognition features for elderly users who cannot type drug names, as reported by China News Service.

Provincial Innovations

Under the NHSA’s framework, provinces have developed unique features tailored to local needs. Jiangsu Province launched “Jiangsu Drug Price Link” in September 2024, covering approximately 32,000 designated pharmacies with no registration required. Hangzhou in Zhejiang created “Smart Drug Search One-Click,” integrating e-prescriptions, inventory, and in-store resources.

Hebei Province introduced a “four-color map” system that uses big data to rate pharmacy price levels: blue for cheapest, green and yellow for mid-range, and red for most expensive. According to Xinhua News Agency, Hebei has sent 56 batches of price alerts covering 87 drugs, with all pharmacies adjusting prices accordingly.

Jiangxi Province’s Pingxiang city added voice recognition and photo-scanning for drug lookup, with real-time price and inventory updates, making the tool accessible to elderly users with lower digital literacy.

Regulatory and Policy Context

The price comparison initiative is part of a broader effort to reform China’s drug pricing system. On April 15, 2026, the State Council published “Opinions on Improving the Drug Price Formation Mechanism,” outlining principles for fair pricing across different sales channels.

Wang Xiaoning, Director of the NHSA Medical Insurance Price and Procurement Department, stated at a State Council press conference that price differences between channels are normal but should not be excessive. “The price comparison mini-programs have been launched in all provinces. Everyone is welcome to pay attention to and make good use of the drug price comparison mini-programs,” Wang said, as reported by Red Star News.

The NHSA has explained that China’s drug pricing operates on multiple levels: new drugs are self-priced by enterprises with oversight, medical insurance negotiation (the famous “soul bargaining”) secures prices for inclusion in the national drug catalog, volume-based procurement drives down costs for off-patent drugs, and regular monitoring applies to drugs not yet suitable for centralized procurement.

Impact on Patients

The nationwide platform has brought tangible benefits, particularly for patients with chronic conditions requiring long-term medication. The NHSA stated that the tool effectively reduces drug purchasing costs, eliminates the tedious process of visiting multiple stores to compare prices, and breaks down information barriers that previously led to overpaying.

For patients with hypertension, diabetes, and other conditions requiring regular medication, the savings can be substantial. The platform also improves purchasing efficiency by allowing patients to check stock availability and store distances in advance, avoiding wasted trips.

What’s Next

The NHSA plans to continue optimizing the platform’s functionality, expanding service scenarios, and developing more intelligent governance tools. Future enhancements may include e-prescription circulation, drug delivery services, and smart early warning systems, potentially creating a fully integrated digital drug purchasing ecosystem.

As the system matures, the transition from “searching everywhere for drugs and repeatedly comparing prices” to “online inquiry and precise purchasing” is expected to become the new normal for Chinese patients.